Fuda Cancer Hospital
Liver cancer stage 2 treatment cost in China typically involves diagnostic imaging like a CT of the chest, which ranges from $300 to $600. Primary treatment options like chemotherapy for breast cancer cost $14,800 to $31,000, while radiation therapy for colorectal cancer runs from $11,500 to $27,500. Total expenses depend on the surgical approach and hospital tier, offering 50-70% savings compared to the US. Top treatment hubs include Beijing, Shanghai, and Guangzhou.
Typical Liver Cancer Stage 2 Treatment Costs in China
Bookimed Expert Insight: Patients seeking advanced alternatives to traditional chemotherapy should consider specialized centers in Guangzhou. Fuda Cancer Hospital is a JCI-accredited facility offering unique minimally invasive technologies like NanoKnife and cryosurgery. This clinic has treated over 30,000 international patients, specializing in late-stage success. For those requiring integrated care, experts like Liuying provide specialized expertise in thermal ablation for liver tumors.
| China | Turkey | Austria | |
| Radiation therapy for colorectal cancer | from $11,500 | from $3,250 | from $12,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
The China Liver Cancer (CNLC) system defines Stage 2 as an intermediate level of liver cancer. It requires preserved liver function (Child-Pugh A or B). The disease must remain localized to the liver. There is no spread to major vessels, lymph nodes, or distant organs.
Bookimed Expert Insight: Chinese oncology centers often prioritize clinical resectability over traditional TNM staging labels. For example, Dr. Liuying at Jinshazhou Hospital manages cases where liver function impacts the plan more than tumor size. Fuda Cancer Hospital successfully treats Stage 2 cases using minimally invasive cryosurgery. This approach helps patients who cannot tolerate standard chemotherapy or major resection.
Patient Consensus: Patients note that staging labels in China may shift after surgery or biopsy. They emphasize confirming if the cancer is resectable or requires alternative therapies like TACE.
Surgery is a primary curative option for Stage 2 liver cancer in China. National guidelines prioritize surgical resection or transplantation for localized tumors. Chinese specialists use the China Liver Cancer staging system to determine operability. Success depends on liver function and tumor location after thorough scans.
Bookimed Expert Insight: Chinese oncology centers often apply a more aggressive surgical criteria than Western hospitals. Some facilities specialize in treating late-stage cancer for over 30,000 international patients. These centers regularly combine resection with specialized technologies like vascular interventional therapy. This approach allows surgeons to operate on tumors previously considered too risky or inoperable.
Patient Consensus: Patients note that liver health often matters more than the stage label itself. Many emphasize that a hepatobiliary surgeon’s expert opinion is vital before deciding against surgery.
China combines immunotherapy with localized treatments by integrating checkpoint inhibitors with procedures like TACE, cryosurgery, or NanoKnife. This multi-modal strategy turns immune-reactive tumors into hot ones to increase response rates. Centers frequently use hepatic artery infusion and ablation to trigger systemic anti-tumor responses through antigen release.
Bookimed Expert Insight: A distinct pattern in China is the aggressive use of downstaging strategies for stage 2 liver cancer. Clinics like Fuda Cancer Hospital utilize JCI-accredited facilities to combine specialized vascular interventional therapy with immunotherapy. This sequence aims to shrink lesions enough for curative surgery rather than relying purely on systemic drugs. Specialists like Dr. Liuying focus on microwave ablation to reduce tumor burden before starting immunotherapy cycles.
Patient Consensus: Patients note that doctors prioritize stabilizing liver function before starting these intense combinations. They also emphasize that the sequence of local treatment followed by immunotherapy helps manage side effects better.
Traditional Chinese Medicine cannot cure Stage 2 liver cancer on its own. Modern interventions like surgical resection or ablation are required to remove tumors. Chinese oncology centers typically use integrative care. They combine Western surgery with herbal formulas to manage side effects.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital demonstrate that successful outcomes rely on multi-modality approaches. They utilize NanoKnife and cryosurgery alongside supportive therapies for over 30,000 international patients. Choosing a clinic with JCI accreditation ensures that these integrative methods meet strict global safety standards. This is vital because incorrect herbal dosages can cause liver toxicity.
Patient Consensus: Patients note that feeling better from herbs does not always mean the tumor is shrinking. They emphasize tracking progress through CT scans or MRI rather than just physical comfort.